

Table 1: Details of the three treatment arms

Treatment arm (Number of patients)	
T + D + CT* (338)	Patients received <u>both tremelimumab 75mg plus durvalumab 1,500mg alongside platinum-based chemotherapy</u> for up to four 21-day cycles, followed by durvalumab once every four weeks until their cancer progressed, and one additional tremelimumab dose.
D + CT* (338)	Patients received <u>durvalumab 1,500mg plus chemotherapy</u> for up to four 21-day cycles, followed by durvalumab once every four weeks until their cancer progressed.
CT* (337)	Patients received <u>chemotherapy</u> for up to six 21-day cycles.

*T: tremelimumab; D: durvalumab; CT: chemotherapy

Table 2: An overview of the median progression-free survival and 12-month progression-free survival rates

Treatment arm (Number of patients)	Median progression-free survival	12-month progression-free survival
T + D + CT* (338)	6.2 months	26.6%
D + CT* (338)	5.5 months	24.4%
CT* (337)	4.8 months	13.1%

*T: tremelimumab; D: durvalumab; CT: chemotherapy

Table 3: An overview of the median overall survival and 24-month overall survival rate

Treatment arm (Number of patients)	Median overall survival	24-month overall survival rate
T + D + CT* (338)	14 months	32.9%
D + CT* (338)	13.3 months	29.6%
CT* (337)	11.7 months	22.1%

*T: tremelimumab; D: durvalumab; CT: chemotherapy